PAOG Announces Plans To Add New Pharmaceutical Product Developments

Rhea-AI Summary

PAO Group, Inc. (OTC Pink: PAOG) is expanding its pharmaceutical pipeline by adding new products while continuing the development of its RespRx CBD treatment for Chronic Obstructive Pulmonary Disease (COPD). The company is currently reviewing this project with its Contract Research Organization (CRO) and industry experts to explore opportunities for acceleration and diversification.

Recent analyses have identified derivative opportunities that may lead to additional pharmaceutical developments, potentially reaching the market faster than RespRx.

Positive

• Expansion of the pharmaceutical pipeline with multiple new products.
• Ongoing development of RespRx CBD may benefit from a potential partnership to accelerate progress.
• Identified derivative opportunities have fast-track potential, likely to reach the market sooner than RespRx.

Negative

• None.

Sandusky, OH, Nov. 05, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

The company has been conducting an in-depth review of its current RespRx CBD pharmaceutical development project with its CRO partner, industry consultants and other pharmaceutical firms in an effort to explore various opportunities to accelerate and diversify development.

As part of the in-depth review, PAOG recently announced entertaining a partnership opportunity that could accelerate the ongoing development of its RespRx CBD.

As the in-depth review continues, PAOG has now identified derivate opportunities from its research to launch additional pharmaceutical product development projects. The identified opportunities PAOG plans to pursue have fast-track potential and are likely to result in a pharmaceutical product reaching market before RespRx.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

FAQ

What plans did PAO Group announce on November 5, 2021?

PAO Group announced plans to add multiple new pharmaceutical products to its pipeline alongside the ongoing development of its RespRx CBD treatment for COPD.

How is PAOG developing its RespRx CBD product?

PAOG is conducting a detailed review of its RespRx CBD project with its CRO partner and industry consultants to explore opportunities for acceleration and diversification.

What did PAOG identify through its recent research?

PAOG identified derivative opportunities from its research that could lead to the launch of new pharmaceutical products, potentially reaching the market before RespRx.